Yale School of Medicine, New Haven, CT, 06510, USA; APT Foundation Pain Treatment Services, New Haven, CT, 06519, USA.
Brown School of Public Health, Providence, RI, 02903, USA.
Drug Alcohol Depend. 2018 Oct 1;191:348-354. doi: 10.1016/j.drugalcdep.2018.07.008. Epub 2018 Aug 22.
BACKGROUND/AIMS: Although nonmedical use of prescription opioids (NMUPO) is a public health problem, few studies have examined the new-onset NMUPO in clinical populations. We estimated NMUPO incidence among veterans in medical care who had received prescription opioid medication and examined correlates of new-onset NMUPO.
Prospective cohort study.
Veterans Health Administration primary care and infectious disease clinics in Atlanta, Baltimore, Bronx, Houston, Los Angeles, Manhattan, Pittsburgh, and Washington, DC.
Patients enrolled in the Veterans Aging Cohort Study wave 3 (2005-2007) who received prescription opioids in the previous year and without lifetime NMUPO were followed at waves 4 and 5 (2008-2011).
Cox proportional hazards regression was used to examine the relationship between duration of prescription opioid receipt and incident NMUPO, adjusting for demographics, alcohol and tobacco use, substance use disorders, psychiatric and medical diagnoses, and medication-related characteristics.
Among eligible participants (n = 815), the median age was 52 (IQR = 47-58) and 498 (59.8%) were Black; 122 (15.0%) reported new-onset NMUPO, for an incidence rate of 5.0 per 100 person-years. In a multivariable Cox model, compared to <30 days, receipt of prescription opioids for 30-180 days (adjusted hazard ratio [AHR] = 1.65 95% CI: 1.06, 2.58) or >180 days (AHR = 1.99, 95% CI: 1.21, 3.29) was associated with incident NMUPO.
Duration of prescription opioid receipt is a risk factor for incident NMUPO among veterans receiving medical care. Providers who prescribe opioids should monitor for NMUPO, especially among those with a longer duration of opioid therapy.
背景/目的:尽管非医疗用途处方类阿片(NMUPO)是一个公共卫生问题,但很少有研究调查临床人群中新发的 NMUPO。我们评估了在接受处方类阿片药物治疗的退伍军人中 NMUPO 的新发病例,并调查了新发病例的相关因素。
前瞻性队列研究。
亚特兰大、巴尔的摩、布朗克斯、休斯顿、洛杉矶、曼哈顿、匹兹堡和华盛顿特区的退伍军人健康管理局初级保健和传染病诊所。
参加退伍军人老龄化队列研究第 3 波(2005-2007 年)的患者,在过去一年中接受过处方类阿片药物治疗且无终身 NMUPO,在第 4 波和第 5 波(2008-2011 年)进行随访。
采用 Cox 比例风险回归分析,调整人口统计学因素、酒精和烟草使用、物质使用障碍、精神和医学诊断以及与药物相关的特征后,研究处方类阿片药物使用时间与新发 NMUPO 之间的关系。
在符合条件的参与者(n=815)中,中位年龄为 52 岁(IQR=47-58),498 人(59.8%)为黑人;122 人(15.0%)报告新发病例 NMUPO,发病率为每 100 人年 5.0 例。在多变量 Cox 模型中,与使用时间<30 天相比,使用时间为 30-180 天(调整后的危险比[AHR] =1.65,95%可信区间:1.06,2.58)或>180 天(AHR=1.99,95%可信区间:1.21,3.29)与 NMUPO 的新发相关。
在接受医疗护理的退伍军人中,处方类阿片药物使用时间的长短是 NMUPO 新发的一个危险因素。开具阿片类药物的医生应监测 NMUPO,特别是在那些接受更长时间阿片类药物治疗的患者中。